Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study
Yasuyoshi Kimura, Toru Koda, Hiroyuki Kurakami, Shigeru Sakamoto, Koji Iwasaki, Kanako Asai, Lindun Ge, Hiroki Kato, Takashi Tsuboi, Noriyuki Matsukawa, Osamu Kano, Dai Matsuse, Masahiko Tomiyama, Masaru Yokoe, Yoshitaka Nagai, Hideki Mochizuki · 2025
Read Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study by Yasuyoshi Kimura, Toru Koda, Hiroyuki Kurakami, Shigeru Sakamoto, Koji Iwasaki, Kanako Asai, Lindun Ge, Hiroki Kato, Takashi Tsuboi, Noriyuki Matsukawa, Osamu Kano, Dai Matsuse, Masahiko Tomiyama, Masaru Yokoe, Yoshitaka Nagai, Hideki Mochizuki (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742159.txt.
Description
Yasuyoshi Kimura and a large team set out the protocol for the MOST-ABLE trial of oral semaglutide in Parkinson's disease, in work from 2025. Proof is growing that GLP-1 drugs may help in Parkinson's, but clinical results are not settled. Their phase 2 trial is multicentre, double-blind and placebo-controlled, with 99 patients at eight sites in Japan.
Patients with early to mid stage disease are split evenly among two tablet doses and placebo, taken daily on top of standard care for 36 weeks. A 12-week off-drug phase follows, to test for lasting disease change. Outcomes span movement scores, quality of life, cognition and brain imaging. Safety and the best dose are also tracked.
Catalog record
| CREATOR | Yasuyoshi Kimura, Toru Koda, Hiroyuki Kurakami, Shigeru Sakamoto, Koji Iwasaki, Kanako Asai, Lindun Ge, Hiroki Kato, Takashi Tsuboi, Noriyuki Matsukawa, Osamu Kano, Dai Matsuse, Masahiko Tomiyama, Masaru Yokoe, Yoshitaka Nagai, Hideki Mochizuki |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |